A look back at the ISPOR Annual International Meeting

Brian KellyLast week, participants from across our enterprise gathered in Philadelphia to contribute to the 20th Annual International Society of Pharmacoeconomics and Outcomes Research (ISPOR) conference. ISPOR advances the policy, science, and practice of pharmacoeconomics (or health economics) and outcomes research (the scientific discipline that evaluates the effect of health care interventions on patient well-being, including clinical, economic, and patient-centered outcomes). 

This meeting is a prime opportunity to convene and exchange ideas with clients, global researchers, thought leaders and industry peers, and in that sense we wasted no opportunity. The annual international meeting, and the ISPOR organization as a whole, is very important to us. To help illustrate that point:

  • William H. Crown, chief scientific officer, Optum Labs, is a longtime contributor to ISPOR, having served as past president and board member. He was recognized with an ISPOR service award for his leadership within the organization last week and we commend him for all of his work.
  • Dr. Brian Solow, chief medical officer for Optum Rx, serves as a North American representative for the ISPOR Health Technology Assessment Council (HTAC) and, as such, participated in the council meeting during the conference.
  • Further, colleagues from Optum, UnitedHealthcare and UnitedHealth Group made it a priority to present and participate in educational symposia, plenary sessions, issue panels, workshops and poster presentations on a wide variety of research topics.
  • The full list of Optum’s contributions to the meeting, spanning from Life Sciences to Optum Global Solutions, Optum Labs to OptumRx, highlights the fact that real-world evidence is having far-reaching implications across health care.

With this year’s annual meeting behind us, we’d like to express our thanks.

Thank you to all who visited our booth in the exhibit hall to talk with us and learn how Optum’s data, consulting and research capabilities offer insights to make the right health care investments.

Thanks also to our partners at SAS who were present in the Optum booth to discuss and share our work on an open data platform to help clients better manage, analyze and share data, in order to dig out data-driven insights. We’re excited about this partnership and look forward to working with other collaborators soon.

We were very encouraged by the level of involvement in this meeting via social media. Thanks to all who connected with us on Twitter at @OptumNews and who engaged with us via the hash tag #ISPORPhila.

Thank you to our fellow thought leaders, researchers and industry peers. We appreciate the lively discussions and thought exchange about the challenges and opportunities we all face.

Finally, congratulations and thank you to all those within our own organization who participated in this year’s meeting.

Brian Kelly, President, Optum Life Sciences

Leave a Reply